RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer Grade1a (very slight effect) Viable tumor cells occupy more than 2/3 of the tumorous area.
SUPPLEMENTARY MATERIALS

Supplementary
Grade1b (slight effect) Viable tumor cells remain in more than 1/3 but less than 2/3 of the tumorous area.
Grade2 (considerable effect) Viable tumor cells remain in less than 1/3 of the tumorous area.
Grade3 (complete response)
No viable tumor cells remain. It is recommended that the finding is confirmed on additional sectioning.
